Allos Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
04 Novembro 2008 - 11:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company focused on developing and commercializing innovative small
molecule drugs for the treatment of cancer, today announced that
members of the Company�s senior management will present a corporate
overview at the Rodman & Renshaw 10th Annual Healthcare
Conference in New York. The Company�s presentation will take place
at 4:55 p.m. (Eastern) on Tuesday, Nov. 11, 2008. There will be a
live webcast of the presentation, which will be accessible through
a link posted on the Allos website home page and investor relations
section. The webcast will be available for replay on Allos� website
through November 21, 2008. About Allos Therapeutics, Inc. Allos
Therapeutics is a biopharmaceutical company focused on developing
and commercializing small molecule therapeutics for the treatment
of cancer.�The Company's lead product candidate, pralatrexate
(PDX), is a novel antifolate currently under evaluation in a
pivotal Phase 2 (PROPEL) trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The PROPEL trial is being
conducted under an agreement reached with the U.S. Food and Drug
Administration under its special protocol assessment, or SPA
process. The Company is also investigating pralatrexate in patients
with non-small cell lung cancer, bladder cancer and a range of
lymphoma subtypes. The Company's other product candidate�is RH1, a
targeted chemotherapeutic agent currently being evaluated in a
Phase 1 trial in patients with advanced solid tumors or
non-Hodgkin�s Lymphoma (NHL). Allos currently retains exclusive
worldwide rights to pralatrexate and RH1 for all indications. For
additional information, please visit the Company�s website at
www.allos.com. Safe Harbor Statement The anticipated presentation
will contain forward-looking statements that involve significant
risks and uncertainties. Additional information concerning these
forward-looking statements and other factors that may cause actual
results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2007 and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in the presentation. All
forward-looking statements are based on information currently
available to the Company on the date thereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics, Inc.